Pen And Injector Drug Delivery Devices Market

Pen And Injector Drug Delivery Devices Market Summary

The global pen and injector drug delivery devices market size was estimated at USD 114.67 billion in 2025 and is projected to reach USD 236.54 billion by 2033, growing at a CAGR of 9.6% from 2026 to 2033. This strong growth is driven by the rising demand for advanced, effective, and user-friendly drug delivery solutions across healthcare settings..

Key drivers include the increasing prevalence of chronic conditions such as diabetes, cancer, and autoimmune disorders that require frequent injections; growing adoption of user-friendly injection tools such as autoinjectors and pen injectors; and continuous technological advancements that enhance safety, accuracy, and patient comfort. In addition, growing biological development, the shift toward home-based care, and greater focus on reducing hospital visits are further supporting market growth.

One of the major drivers of the pen and injector drug delivery devices market is the increasing prevalence of chronic diseases, along with the rapid growth of the geriatric population. Chronic conditions such as diabetes, cancer, cardiovascular diseases, and autoimmune disorders often require regular or long-term medication delivered through injections for fast and effective therapeutic action. According to the IDF’s 2021 report, about 537 million people around the world had diabetes, which means roughly 1 in 10 people were affected. The number is expected to rise sharply, reaching 783 million people by 2045. As these diseases become more common in the world, the demand for reliable and easy-to-use injectable devices continues to increase. In addition, the aging population faces multiple health issues and typically requires frequent medical treatments, including injectable drugs. According to the recent population estimates and projections by UN DESA’s Population Division, the number of people aged 60 and older is projected to reach 1.5 billion by 2050, representing about 1 in 6 people globally. This demographic shift is supporting the need for convenient, safe, and precise delivery systems that support both clinical use and home-based care, thereby contributing significantly to market growth.

Technological advancements in drug delivery systems are driving the growth of pen and injector drug delivery devices. Innovations have made injection devices safer, more efficient, and easier for patients to use. Features such as smart autoinjectors with digital monitoring, needle-free injection technologies, and improved safety mechanisms help ensure accurate dosing and reduce the risk of needle injuries. Advancements in materials and device design also enhance comfort and support self-use at home, which is becoming increasingly important for people managing chronic diseases. For instance, in October 2024, BD and Ypsomed announced a strategic collaboration to integrate BD’s Neopak XtraFlow glass prefillable syringe, featuring a shorter 8 mm needle and a thinner-wall cannula, with Ypsomed’s YpsoMate 2.25 autoinjector. This design makes high-viscosity biologic drugs easier to inject for patients self-administering at home, and the two-step injector is purpose-built to assist users with

limited grip or vision. Such technological improvements encourage adoption and support significant market growth.

Global Pen And Injector Drug Delivery Devices Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global pen and injector drug delivery devices market report on the basis of product, therapeutic use, end use, and region.

Product Outlook (Volume, Units; Revenue, USD Billion, 2021 - 2033)

Injectors

GLP-1 Agonists

Hormone Therapies

Biologics

Others

Pen

GLP-1 Agonists

Insulin

Hormone Therapies

Others

Therapeutic Use Outlook (Volume, Units; Revenue, USD Billion, 2021 - 2033)

Autoimmune Disorders

Hormonal Disorders

Oncology

Obesity

Diabetes Mellitus

Others

End Use Outlook (Volume, Units; Revenue, USD Billion, 2021 - 2033)

Hospitals

Homecare Settings

Others

Regional Outlook (Volume, Units; Revenue, USD Billion, 2021 - 2033)

North America

U.S.

Canada

Mexico

Europe

UK

Germany

France

Italy

Spain

Norway

Sweden

Denmark

Asia

China

Japan

India

Thailand

South Korea

Saudi Arabia

UAE

Kuwait

Please note The report will be delivered in 2-3 business days upon order notification. Show more